Replies to post #151791 on Biotech Values

[turtlepower]

Also mentioned was the PROC trial with VTX2337, the lead compound for VentiRx. The PR notes that the compound is partnered with CELG and not with ARRY. I need to read up on what the terms are.

http://www.ventirx.com/assets/pdfs/Final_GOG_Press_Release.pdf

[poorgradstudent]

ARRY / ONXX:

6. Squarer interestingly (IMHO) metioned that ARRY's relationship with ONXX is "positive" and ONXX/ARRY have had discussions about co-funding and sharing the costs of 520+carfilzomib trials going forward. Squarer reiterated that ARRY still intends to go it alone on 520 and 614 but ARRY may be open to geographies outside the U.S. and Europe. (Does anyone see ONXX as a potential partner, at a minimum, for ARRY in the future provided 520 and/or 614 data pans out? Obviously ONXX has a hem-onc interest. Just thought Squarer's comments here were interesting; don't recall ARRY ever mentioning any discussions with ONXX before.)

Being more familiar with the ONXX side rather than the ARRY side, these are the points to come to mind:

For: It would be consistent for ONXX because they've been rather aggressive with carfilzomib. I think ONXX believes they have an inherent edge versus velcade and they're already embarked on that journey, so a combo with a novel drug may be a first shot at competing against revlimid.

For: I'm a broken record on this, but ONXX's preclinical work is not the envy of the biotech sector, so trying to leverage their cash flow with a few novel shots on goal would make sense for them.

For: Monotherapy is the easiest (and arguably most reliable) way to market for multiple myeloma. If ARRY is trying to hedge their bets then it would be a good fit.

Against: As an ONXX shareholder, I would not be in favour of an in-licensing. Due to point #3, I think that ARRY is showing their hand and I would use that as leverage. Maybe provide some free drug and help a little bit with trial costs, but not much more.

[mcbio]

ARRY - 797 ACR PR

http://finance.yahoo.com/news/array-biopharma-present-clinical-data-194900124.html

Array BioPharma To Present Clinical Data On ARRY-797 At The 2012 American College Of Rheumatology Annual Meeting

BOULDER, Colo., Nov. 6, 2012 /PRNewswire/ -- Array BioPharma Inc. (ARRY) announced that an abstract discussing the final Phase 2 trial results with ARRY-797 in patients with osteoarthritis pain will be presented at the 2012 American College of Rheumatology Annual Meeting in Washington, D.C. This abstract includes data on ARRY-797's analgesic effect and markers of disease modification. In addition, biomarkers of cartilage (COMP) and bone (CTX-I) degradation were assessed. ARRY-797 treatment resulted in statistically significant decreases in COMP and CTX-I at week 4 (decreases of 10% and 38% versus placebo, respectively). The decrease in CTX-I was sustained and returned to baseline by the follow-up visit. The abstract concludes that further evaluation of the potential for disease modifying activity is warranted.

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)

The abstract can be accessed through the American College of Rheumatology Annual Meeting website, http://www.rheumatology.org/apps/MyAnnualMeeting/ExploreMeeting. After the presentation, the poster will be available as a PDF on Array's website at www.arraybiopharma.com.

Poster:

A Randomized, Placebo-Controlled Phase 2 Study of ARRY-797 in Patients with Osteoarthritis Pain Refractory to NSAID Treatment Showed Statistically Significant Improvements in WOMAC Pain and in Biomarkers of Bone and Cartilage Degradation

Session:

Late Breaking Abstracts

Date:

Tuesday, November 13, 2012

Time:

9:00 - 11:00 AM Eastern Time

Location:

Walter E. Washington Convention Center - Poster Hall (Hall B)


Array announced in July 2012 that ARRY-797, a non-opioid, met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs). Patients in all treatment groups continued using NSAIDs throughout the trial. ARRY-797 is a novel, oral, selective p38 inhibitor with a mechanism of action unique from that of currently approved pain medications. Given our internal focus on hematology/oncology, Array is in active discussions with potential partners to maximize the value of this drug.

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly-owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune / Roche), having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013. For more information on Array, please go to www.arraybiopharma.com.